FDA Greenlights Mesoblast’s Resubmission for Pediatric Graft-Versus-Host Disease Treatment

Photo of author
Written By Kevin MacDonald

In a pivotal development earlier this week, Mesoblast Limited (NASDAQ: MESO) received a significant nod from the U.S. Food and Drug Administration (FDA), paving the way for a major advancement in the treatment of pediatric patients suffering from steroid-refractory acute graft versus host disease (SR-aGVHD).

The FDA’s reconsideration of clinical data from Mesoblast’s Phase 3 study, MSB-GVHD001, marks a turning point, signalling the data’s sufficiency to back the submission of a Biologics License Application (BLA) for remestemcel-L, a promising therapeutic intervention for this critical condition.

Mesoblast’s Path Forward

Dr. Silviu Itescu, CEO of Mesoblast, expressed gratitude towards the FDA for their collaborative spirit and clear guidance, which has instilled a renewed confidence within the company to proceed with the BLA refiling for remestemcel-L.

Credit: DepositPhotos

Targeting a submission in the upcoming quarter, Mesoblast is poised to address and resolve any lingering product characterization issues, demonstrating a steadfast commitment to bringing this vital treatment to children in dire need.

A Journey Through Regulatory Challenges

Mesoblast’s journey to this point has been marked by regulatory challenges and milestones.

In August 2023, the FDA issued a complete response letter in relation to Mesoblast’s resubmission for remestemcel-L, specifically for pediatric SR-aGVHD, calling for additional data.

This prompted the company to outline plans for a targeted, controlled study among high-risk adult patients, aimed at addressing the FDA’s requirements.

Notably, the FDA’s Oncologic Drugs Advisory Committee had previously shown strong support for remestemcel-L, with a 9:1 vote in favor of its efficacy for the pediatric population in August 2020.

However, further recommendations by the FDA in September 2020 underscored the need for additional steps to secure approval.

The BLA resubmission in January 2023 was bolstered by compelling long-term follow-up data from the Phase 3 trial conducted by the Center for International Blood and Marrow Transplant Research.

This data showcased a remarkable 50% survival rate over four years of follow-up for patients treated with remestemcel-L, reinforcing the treatment’s potential life-saving impact.

Accelerated Approval Pathway for Another Mesoblast Treatment

Earlier in the month, the FDA endorsed an accelerated approval pathway for another of Mesoblast’s innovative treatments, rexlemestrocel-L, targeting end-stage ischemic heart failure with reduced ejection fraction (HFrEF) and a left ventricular assist device (LVAD).

This endorsement underscores the FDA’s recognition of Mesoblast’s contributions to addressing unmet medical needs through its pioneering therapies.

Market Reaction and Future Prospects

Following the FDA’s positive feedback, Mesoblast’s shares experienced a significant surge, climbing 75.90% to $3.87.

This market reaction reflects the investor confidence in Mesoblast’s potential to transform the treatment landscape for SR-aGVHD and beyond.

Credit: DepositPhotos

As Mesoblast prepares for the next steps, the healthcare and investment communities eagerly anticipate the impact of remestemcel-L on pediatric patients grappling with SR-aGVHD.

This development not only represents a breakthrough for Mesoblast but also offers hope to families and children facing this challenging condition, potentially setting a new standard in care and treatment efficacy.

The company stands as a prominent investment option for discerning investors who are prepared to buy and hold for the long term.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.